Intravenous immunoglobulin for the treatment of clostridium difficile infection: A review

Marwan S. Abougergi, John H. Kwon

Research output: Contribution to journalReview article

72 Citations (Scopus)

Abstract

Clostridium difficile infection (CDI) has increased sharply in incidence, mortality rate, and burden on the healthcare system over the past decade. Therefore, novel treatment modalities have been developed, including intravenous immunoglobulin (IVIG). The level of immune response to Clostridium difficile colonization is the major determinant of the magnitude and duration of clinical manifestations. This effect is mediated predominantly by serum IgG anti-toxin A antibodies. Based on this finding, anti-toxin A and B antibodies were successfully used in multiple in vitro and in vivo experimental settings to passively immunize hamsters in CDI models. In humans, IVIG was used as the source of those antibodies. Fifteen small, mostly retrospective and non-randomized reports documented IVIG's success in the treatment of protracted, recurrent, or severe CDI. Diarrhea resolution rates were higher in the former patient group, but the recurrence rates were similar. IVIG mechanism of action is neutralization of mainly toxin A through IgG anti-toxin A antibodies. Purified anti-toxin A and B antibodies were successfully used to decrease CDI recurrence rates among patients with no or one previous CDI episodes. In conclusion, the efficacy of IVIG for CDI treatment in animal models has been convincingly demonstrated. However, only few small non-randomized, mostly uncontrolled reports have been published on human subjects. A phase II trial results support the use of purified anti-toxin A and B antibodies to decrease CDI recurrence rates. Therefore, IVIG should currently only be used as adjunct therapy until results from large, randomized controlled trials are available.

Original languageEnglish (US)
Pages (from-to)19-26
Number of pages8
JournalDigestive Diseases and Sciences
Volume56
Issue number1
DOIs
StatePublished - Jan 1 2011

Fingerprint

Clostridium Infections
Clostridium difficile
Intravenous Immunoglobulins
Antibodies
Therapeutics
Recurrence
Cricetinae
Diarrhea
Randomized Controlled Trials
Animal Models
Delivery of Health Care
Mortality
Incidence

Keywords

  • Clostridium difficile/drug effects
  • Immunoglobulins
  • Immunomodulation
  • Infectious diarrhea
  • Intravenous/therapeutic use
  • Nosocomial infection

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology

Cite this

Intravenous immunoglobulin for the treatment of clostridium difficile infection : A review. / Abougergi, Marwan S.; Kwon, John H.

In: Digestive Diseases and Sciences, Vol. 56, No. 1, 01.01.2011, p. 19-26.

Research output: Contribution to journalReview article

@article{932068e792c64c46910502429778c423,
title = "Intravenous immunoglobulin for the treatment of clostridium difficile infection: A review",
abstract = "Clostridium difficile infection (CDI) has increased sharply in incidence, mortality rate, and burden on the healthcare system over the past decade. Therefore, novel treatment modalities have been developed, including intravenous immunoglobulin (IVIG). The level of immune response to Clostridium difficile colonization is the major determinant of the magnitude and duration of clinical manifestations. This effect is mediated predominantly by serum IgG anti-toxin A antibodies. Based on this finding, anti-toxin A and B antibodies were successfully used in multiple in vitro and in vivo experimental settings to passively immunize hamsters in CDI models. In humans, IVIG was used as the source of those antibodies. Fifteen small, mostly retrospective and non-randomized reports documented IVIG's success in the treatment of protracted, recurrent, or severe CDI. Diarrhea resolution rates were higher in the former patient group, but the recurrence rates were similar. IVIG mechanism of action is neutralization of mainly toxin A through IgG anti-toxin A antibodies. Purified anti-toxin A and B antibodies were successfully used to decrease CDI recurrence rates among patients with no or one previous CDI episodes. In conclusion, the efficacy of IVIG for CDI treatment in animal models has been convincingly demonstrated. However, only few small non-randomized, mostly uncontrolled reports have been published on human subjects. A phase II trial results support the use of purified anti-toxin A and B antibodies to decrease CDI recurrence rates. Therefore, IVIG should currently only be used as adjunct therapy until results from large, randomized controlled trials are available.",
keywords = "Clostridium difficile/drug effects, Immunoglobulins, Immunomodulation, Infectious diarrhea, Intravenous/therapeutic use, Nosocomial infection",
author = "Abougergi, {Marwan S.} and Kwon, {John H.}",
year = "2011",
month = "1",
day = "1",
doi = "10.1007/s10620-010-1411-2",
language = "English (US)",
volume = "56",
pages = "19--26",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Intravenous immunoglobulin for the treatment of clostridium difficile infection

T2 - A review

AU - Abougergi, Marwan S.

AU - Kwon, John H.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Clostridium difficile infection (CDI) has increased sharply in incidence, mortality rate, and burden on the healthcare system over the past decade. Therefore, novel treatment modalities have been developed, including intravenous immunoglobulin (IVIG). The level of immune response to Clostridium difficile colonization is the major determinant of the magnitude and duration of clinical manifestations. This effect is mediated predominantly by serum IgG anti-toxin A antibodies. Based on this finding, anti-toxin A and B antibodies were successfully used in multiple in vitro and in vivo experimental settings to passively immunize hamsters in CDI models. In humans, IVIG was used as the source of those antibodies. Fifteen small, mostly retrospective and non-randomized reports documented IVIG's success in the treatment of protracted, recurrent, or severe CDI. Diarrhea resolution rates were higher in the former patient group, but the recurrence rates were similar. IVIG mechanism of action is neutralization of mainly toxin A through IgG anti-toxin A antibodies. Purified anti-toxin A and B antibodies were successfully used to decrease CDI recurrence rates among patients with no or one previous CDI episodes. In conclusion, the efficacy of IVIG for CDI treatment in animal models has been convincingly demonstrated. However, only few small non-randomized, mostly uncontrolled reports have been published on human subjects. A phase II trial results support the use of purified anti-toxin A and B antibodies to decrease CDI recurrence rates. Therefore, IVIG should currently only be used as adjunct therapy until results from large, randomized controlled trials are available.

AB - Clostridium difficile infection (CDI) has increased sharply in incidence, mortality rate, and burden on the healthcare system over the past decade. Therefore, novel treatment modalities have been developed, including intravenous immunoglobulin (IVIG). The level of immune response to Clostridium difficile colonization is the major determinant of the magnitude and duration of clinical manifestations. This effect is mediated predominantly by serum IgG anti-toxin A antibodies. Based on this finding, anti-toxin A and B antibodies were successfully used in multiple in vitro and in vivo experimental settings to passively immunize hamsters in CDI models. In humans, IVIG was used as the source of those antibodies. Fifteen small, mostly retrospective and non-randomized reports documented IVIG's success in the treatment of protracted, recurrent, or severe CDI. Diarrhea resolution rates were higher in the former patient group, but the recurrence rates were similar. IVIG mechanism of action is neutralization of mainly toxin A through IgG anti-toxin A antibodies. Purified anti-toxin A and B antibodies were successfully used to decrease CDI recurrence rates among patients with no or one previous CDI episodes. In conclusion, the efficacy of IVIG for CDI treatment in animal models has been convincingly demonstrated. However, only few small non-randomized, mostly uncontrolled reports have been published on human subjects. A phase II trial results support the use of purified anti-toxin A and B antibodies to decrease CDI recurrence rates. Therefore, IVIG should currently only be used as adjunct therapy until results from large, randomized controlled trials are available.

KW - Clostridium difficile/drug effects

KW - Immunoglobulins

KW - Immunomodulation

KW - Infectious diarrhea

KW - Intravenous/therapeutic use

KW - Nosocomial infection

UR - http://www.scopus.com/inward/record.url?scp=79151476267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79151476267&partnerID=8YFLogxK

U2 - 10.1007/s10620-010-1411-2

DO - 10.1007/s10620-010-1411-2

M3 - Review article

C2 - 20924675

AN - SCOPUS:79151476267

VL - 56

SP - 19

EP - 26

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 1

ER -